SGLT2 inhibitors, including canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin, have demonstrated effective glycemic control in patients with type 2 diabetes mellitus (T2DM), both as monotherapy and as add-on therapy, along with additional benefits such as weight loss and blood pressure reduction (22, 23). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.